Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD:… EP News Bureau May 20, 2025 GlobalData’s latest analysis reveals that tezepelumab, evaluated in the Phase IIa COURSE trial, achieved a 26 per cent reduction…
GSK’s Nucala highlights IL-5 inhibition in reducing COPD exacerbations in eosinophilic patients:… EP News Bureau May 19, 2025 In both groups, Nucala significantly lowered the rate of exacerbations requiring emergency department (ED) visits or…
USFDA approves Nucala to treat hypereosinophilic syndrome EP News Bureau Sep 26, 2020 The approval granted to GlaxoSmithKline is the first approval for HES patients in nearly 14 years
